Global Gestational Trophoblastic Disease Research Report: By Type (Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, and Others), by Treatment (Surgery, Suction Dilation and Curettage, and Others), by End User—Forecast Till 2027
Market Highlights
Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.
The global gestational trophoblastic disease market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6558
Regional Analysis
The market in the Americas is expected to dominate the global Gestational Trophoblastic Disease market during the forecast period owing to the increased awareness about the disease and the favorable reimbursement scenario in this region. Additionally, the rise in a number of marketing approvals, as well as product approvals in the field of oncology. The European market is expected to be the second-largest due to the substantial support of the government in research and development in this field. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing disposable income, increasing patient population, and discrepancies between hospital- and population-based data. The market in the Middle East and Africa is likely to account for the smallest share of the global gestational trophoblastic disease market. The growth of the market in this region can be attributed to the growing expenditure for the healthcare sector and developing healthcare infrastructure.
Segmentation
The global gestational trophoblastic disease market has been segmented into type, treatment, and end-user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. Surgical procedures are the most preferred treatment option by the doctors, which is why it is anticipated to be the largest growing segment in the market, whereas chemotherapy segment is the fastest-growing, as there are new innovations coming up in the chemotherapy field such as single-agent and multiagent chemotherapies.
The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end-user, has been segmented into hospital and clinics, diagnostic centers, and others.
Key Players
Some of the key players in the global gestational trophoblastic disease market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, Antares Pharma, Mylan N.V., Novartis AG, BP Pharmaceuticals Laboratories Company, Fresenius Kabi AG, Accord Healthcare, Inc., Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc. and Merck.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gestational-trophoblastic-disease-market-6558
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Diabetes mellitus classification It has two categories, they are:diabetes 1 anddiabetes 2Type 2 has two other sub types, they are:gestational andpre-diabetes"Diabetes 1" is also being called as Male Diabetes Solution Review childhood-onset, juvenile, and insulin-dependent diabetes mellitus (IDDM).
Likewise, "diabetes 2" is also being called as adult-onset, obesity-related, and non-insulin-dependent diabetes mellitus (NIDDM).Diabetes 1 It is characterized by loss of the insulin producing beta cells in the pancreas which leads to insulin deficiency.
There is no known preventive measure against type 1, which causes approximately 10% of cases.
It can affect children or adults but was previously termed "juvenile or childhood-onset diabetes" because it represents a majority of the cases in children.Diabetes 2 It is characterized by insulin resistance which may be combined with relatively reduced insulin secretion.
However, the specific defects are not known, but excess fat deposits in the muscle cell are assumed to be the cause.
As the disease progresses, due to low level of insulin secretion a therapeutic replacement of insulin often becomes necessary.Gestational diabetes mellitus (GDM) It is a sub class of type 2, involving a combination of relatively inadequate insulin secretion and insulin sensitivity.
